Cases & Deals

  • Home
  • Practices
  • PTC Therapeutics develops global patent portfolio for small molecule therapeutics

Share

PTC Therapeutics develops global patent portfolio for small molecule therapeutics

February 2004

Client(s) PTC THERAPEUTICS, INC.

Jones Day represents PTC Therapeutics, Inc. in the establishment of a global patent portfolio related to nonsense mutation suppressor TRANSLARNA® for the treatment of Duchenne Muscular Dystrophy ("DMD") and alternative splicing compounds for the treatment of Spinal Muscular Atrophy ("SMA").

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.